AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.
Haferlach
C
C
Dicker
F
F
Kohlmann
A
A
Schindela
S
S
Weiss
T
T
Kern
W
W
Schnittger
S
S
Haferlach
T
T
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002871:Chromosome Banding; D017353:Gene Deletion; D020869:Gene Expression Profiling; D015321:Gene Rearrangement; D011905:Genes, ras / Q000235:genetics*; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology; D025542:Neurofibromin 1 / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
D014408:Biomarkers, Tumor; C095514:CBFbeta-MYH11 fusion protein; D025542:Neurofibromin 1; D015514:Oncogene Proteins, Fusion